Endovascular therapy for MeVO stroke: ongoing trials скачать в хорошем качестве

Endovascular therapy for MeVO stroke: ongoing trials

Johanna Ospel, MD, University of Calgary, Calgary, Alberta, Canada, explains the uncertainty regarding the use of endovascular thrombectomy (EVT) in acute ischemic strokes due to medium vessel occlusions (MeVOs). In MeVO strokes (M2/3, A2/3, and P2/3 segment occlusions), the occluded vessel – and therefore area of ischemic damage – is smaller than in LVO stroke, meaning patients have better functional outcomes. Additionally, the smaller vessels are harder to get to and more fragile, making treatment more technically challenging. Dr Ospel notes that these factors mean there is less to gain and more to lose compared with LVO strokes, and more evidence is needed to shed light on the risk:benefit ratio. There is currently a lack of strong evidence of argue for or against the use of EVT in the setting of MeVOs, but several ongoing, large scale trials will address this question, including ESCAPE-MeVO (NCT05151172), DISTAL (NCT05029414), DISCOUNT (NCT05030142), and FRONTIER-AP. This interview took place during the International Stroke Conference 2024 in Phoenix, AZ. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.